These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 20336034)

  • 1. Combination oral contraceptives and the risk of venous thromboembolism.
    Med Lett Drugs Ther; 2010 Mar; 52(1334):23-4. PubMed ID: 20336034
    [No Abstract]   [Full Text] [Related]  

  • 2. [Diffuse symptoms in young women may indicate venous thromboembolism. Important to ask about the use of combined hormonal contraception].
    Milsom I; von Sydow H; Thörn AB; Björkelund C; Odlind V
    Lakartidningen; 2012 Sep 19-26; 109(38):1680-2. PubMed ID: 23094400
    [No Abstract]   [Full Text] [Related]  

  • 3. [Hormonal contraception and risk of venous thromboembolism: When to ask for an assessment of hemostasis? Which parameters?].
    Plu-Bureau G; Horellou MH; Gompel A; Conard J
    Gynecol Obstet Fertil; 2008 Apr; 36(4):448-54. PubMed ID: 18424163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yasmin and venous thromboembolism: new case reports.
    López M; Vayá A; Martínez Triguero ML; Contreras MT; Todolí J; Ricart A; Laiz B
    Clin Hemorheol Microcirc; 2009; 42(1):65-9. PubMed ID: 19363241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The risk of deep venous thrombosis with oral contraceptives containing drospirenone.
    Dunn N
    BMJ; 2011 Apr; 342():d2519. PubMed ID: 21511807
    [No Abstract]   [Full Text] [Related]  

  • 6. Epidemiology of hormone-related venous thromboembolism.
    Middeldorp S
    Thromb Res; 2009; 123 Suppl 2():S65-9. PubMed ID: 19217480
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical profile and recurrence rate in women with venous thromboembolism during combined hormonal contraceptive use: a prospective cohort study.
    van Vlijmen EF; Mäkelburg AB; Knol HM; Tichelaar VI; Kluin-Nelemans HC; Veeger NJ; Meijer K
    Br J Haematol; 2016 Feb; 172(4):636-8. PubMed ID: 26105591
    [No Abstract]   [Full Text] [Related]  

  • 8. [Contraception and venous thromboembolism].
    Blondon M; Casini A; Fontana P; Hugon-Rodin J
    Rev Med Suisse; 2020 Dec; 16(718):2383-2386. PubMed ID: 33300698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Routines for first prescription of oral contraceptives].
    Sandø AD; Aanes SG; Slørdal L; Spigset O
    Tidsskr Nor Laegeforen; 2010 Dec; 130(23):2344-8. PubMed ID: 21139658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exogenous hormones, the risk of venous thromboembolism, and activated protein C resistance.
    Mueck AO
    Menopause; 2010; 17(6):1099-103. PubMed ID: 20975607
    [No Abstract]   [Full Text] [Related]  

  • 11. Drospirenone and VTE.
    Leppée M; Eric M; Culig J
    J Fam Plann Reprod Health Care; 2010 Jan; 36(1):44. PubMed ID: 20067674
    [No Abstract]   [Full Text] [Related]  

  • 12. Combined oral contraceptives, venous thromboembolism, and the problem of interpreting large but incomplete datasets.
    Dinger J; Shapiro S
    J Fam Plann Reprod Health Care; 2012 Jan; 38(1):2-6. PubMed ID: 22128104
    [No Abstract]   [Full Text] [Related]  

  • 13. Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism.
    Bitzer J; Amy JJ; Beerthuizen R; Birkhäuser M; Bombas T; Creinin M; Darney PD; Vicente LF; Gemzell-Danielsson K; Imthurn B; Jensen JT; Kaunitz AM; Kubba A; Lech MM; Mansour D; Merki G; Rabe T; Sedlecki K; Serfaty D; Seydoux J; Shulman LP; Sitruk-Ware R; Skouby SO; Szarewski A; Trussell J; Westhoff C
    Eur J Contracept Reprod Health Care; 2013 Jun; 18(3):143-7. PubMed ID: 23578274
    [No Abstract]   [Full Text] [Related]  

  • 14. Contraceptive for obese women: considerations.
    Kelsey B
    Nurse Pract; 2010 Mar; 35(3):24-31; quiz 31-2. PubMed ID: 20164732
    [No Abstract]   [Full Text] [Related]  

  • 15. Difference between drospirenone-containing oral contraceptives and other oral contraceptives related to risk of venous thromboembolism.
    Leppée M; Culig J
    J Fam Plann Reprod Health Care; 2012 Apr; 38(2):137-8. PubMed ID: 22454018
    [No Abstract]   [Full Text] [Related]  

  • 16. Oral contraceptives, hormone therapy and cardiovascular risk.
    Shapiro S
    Climacteric; 2008 Oct; 11(5):355-63. PubMed ID: 18781479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of venous thromboembolism in users of combined oral contraceptives. Risk is particularly high with first use of oral contraceptives.
    Vandenbrouke JP; Bloemenkamp KW; Rosendaal FR; Helmerhorst FM
    BMJ; 2000 Jan; 320(7226):57-8. PubMed ID: 10671043
    [No Abstract]   [Full Text] [Related]  

  • 18. Sex hormone-binding globulin: not a surrogate marker for venous thromboembolism in women using oral contraceptives.
    Stanczyk FZ; Grimes DA
    Contraception; 2008 Sep; 78(3):201-3. PubMed ID: 18692609
    [No Abstract]   [Full Text] [Related]  

  • 19. European agency defends existing advice on later generation contraceptive pills.
    Arie S
    BMJ; 2013 Jan; 346():f279. PubMed ID: 23319580
    [No Abstract]   [Full Text] [Related]  

  • 20. Hormone-based contraceptive therapy and risk of venous thromboembolism in young women.
    Roberts H
    Clin Adv Hematol Oncol; 2010 May; 8(5):307-9. PubMed ID: 20551888
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.